Cindy Yang, S. Y.
Lien, Scott C.
Wang, Ben X.
Clouthier, Derek L.
Hanna, Youstina
Cirlan, Iulia
Zhu, Kelsey
Bruce, Jeffrey P.
El Ghamrasni, Samah http://orcid.org/0000-0003-4346-1360
Iafolla, Marco A. J.
Oliva, Marc http://orcid.org/0000-0001-5352-8130
Hansen, Aaron R.
Spreafico, Anna
Bedard, Philippe L. http://orcid.org/0000-0002-6771-2999
Lheureux, Stephanie
Razak, Albiruni
Speers, Vanessa
Berman, Hal K. http://orcid.org/0000-0001-7524-7911
Aleshin, Alexey
Haibe-Kains, Benjamin
Brooks, David G.
McGaha, Tracy L. http://orcid.org/0000-0003-4721-9301
Butler, Marcus O. http://orcid.org/0000-0002-9840-7057
Bratman, Scott V. http://orcid.org/0000-0001-8610-4908
Ohashi, Pamela S.
Siu, Lillian L. http://orcid.org/0000-0002-3500-0540
Pugh, Trevor J. http://orcid.org/0000-0002-8073-5888
Funding for this research was provided by:
Terry Fox Research Institute
Article History
Received: 9 October 2020
Accepted: 6 August 2021
First Online: 26 August 2021
Competing interests
: D.L.C. is currently an employee of AstraZeneca and had been employed by Ipsen and Pfizer after his involvement in this project. P.L.B. provides consultation for Sanofi (compensated for institution), Roche/Genentech (uncompensated), Bristol-Myers Squibb (uncompensated), and Pfizer (uncompensated); and receives research support (institutional) from Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Roche/Genentech, AstraZeneca/Medimmune, Merck, Nektar Therapeutics, Servier, Seattle Genetics, PTC Therapeutics, Lilly, Oncothyreon. A.S. provides consultation for Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), and Oncorus (compensated); and receives research support (institutional) from Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Array Biopharma. A.R.H. provides consultation for Merck (compensated), GlaxoSmithKline (compensated); and receives research support (institutional) from Genentech/Roche, Merck, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, Boston Biomedical, Boehringer-Ingelheim, AstraZeneca/Medimmune, Janssen Oncology/Johnson & Johnson, and Karyopharm. A.R.A.R. provides consultation for Lilly (compensated), Merck (compensated), and Boehringer-Ingelheim (compensated); receives honoraria from Boehringer-Ingelheim; and receives research support (institutional) from CASI Pharmaceuticals, Boehringer-Ingelheim, Lilly, Novartis, Deciphera, Karyopharm, Pfizer, Roche/Genentech, Boston Biomedical, Bristol-Myers Squibb, AstraZeneca/MedImmune, Amgen, GlaxoSmithKline, Blueprint Medicines, Merck, Abbvie, and Adaptimmune. S.L. provides consultation for Merck (compensated), AstraZeneca/Medimmune (compensated); and receives research support (institutional) from Roche/Genentech, AstraZeneca/Medimmune, Merck, and Tesaro. A.A. is an employee of Natera, Inc. S.V.B. provides consultation for Bristol-Myers Squibb; receives research support from Nektar Therapeutics; and is a co-inventor on a patent application relating to circulating tumor DNA mutation detection technology (US14/774,518: Identification and Use of Circulating Nucleic Acid Tumor Markers; licensed to Roche Molecular Diagnostics) and on a patent application relating to ctDNA methylation analysis technology (PCT/CA2018/000203: Cancer Detection, Classification, Prognostication, Therapy Prediction, and Therapy Monitoring Using Methylome Analysis). P.S.O. is an SAB member for Symphogen Inc and Providence Therapeutics. L.L.S. provides consultation for Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus (compensated), Symphogen (compensated), Seattle Genetics (compensated), GlaxoSmithKline (compensated), Voronoi (compensated), Treadwell Therapeutics (compensated), Arvinas (compensated), Tessa (compensated), and Navire (compensated); receives research support (institutional) from Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks, and Avid; and is a stockholder in Agios (spouse), Treadwell Therapeutics (spouse). T.J.P. provides consultation for Illumina, Merck, Chrysalis Biomedical Advisors and the Canadian Pension Plan Investment Board (compensated); and receives research support (institutional) from Roche/Genentech. All other authors have no other competing interests to report.